Targeting the DNA Damage Response for Anti-Cancer Therapy

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has als...

Celý popis

Uloženo v:
Podrobná bibliografie
Médium: Elektronický zdroj E-kniha
Jazyk:angličtina
Vydáno: Cham : Springer International Publishing, 2018.
Vydání:1st ed. 2018.
Edice:Cancer Drug Discovery and Development,
Témata:
Cancer research.
Gene therapy.
ISBN:9783319758367
ISSN:2196-9906
On-line přístup: Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Obsah:
  • 1. Targeting DNA repair in anti-cancer treatments
  • 2. The DNA damage response: roles in cancer etiology and treatment
  • 3. Control of DNA Replication by ATR
  • 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors
  • 5. Targeting ATR for cancer therapy: ATR-targeted drug candidates
  • 6. ATM: its recruitment, activation, signalling and contribution to tumour suppression
  • 7. Pre-clinical profile and expectations for pharmacological ATM inhibition
  • 8. Targeting ATM for cancer therapy: Prospects for drugging ATM
  • 9. Targeting Chk1 for cancer therapy: rationale, progress and prospects
  • 10. Preclinical profiles and contexts for CHK1 and CHK2 inhibitors
  • 11. Clinical development of CHK1 inhibitors
  • 12. Established and emerging roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
  • 13. Targeting DNA-PK as a therapeutic approach in oncology
  • 14. Dbait: a new concept of DNA repair pathways inhibitor from bench to bedside
  • 15. Alternative Non Homologous End-joining: Mechanisms and Targeting Strategies in Cancer.

Podobné jednotky